BioPharmSignal logoBioPharmSignal

Biotech News

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma (BNTC)Benitec BiopharmaEarnings

BNTC (BNTC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is bntc.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

BNTCBenitec Biopharma2026-09-14 20:00 EST

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

BNTCBenitec Biopharma2026-02-12 13:30 EST

Benitec Biopharma Releases Second Quarter 2026 Financial Results and Provides Operational Update

BNTXBioNTech2026-10-20 10:45 EST

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

ABUSArbutus2025-11-13 12:30 EST

Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PHIOPhio Pharmaceuticals2023-11-09 21:30 EST

Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

ABUSArbutus2026-08-12 11:30 EST

Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update

BNTXBioNTech2026-08-04 10:45 EST

BioNTech Announces Second Quarter 2026 Financial Results and Corporate Update

PHARPharming Group2026-07-30 05:00 EST

Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader therapeutic use

PHARPharming Group2026-07-16 06:00 EST

Pharming Group to report second quarter and first half 2026 financial results and provide business update on July 30

BPTHBio-Path Holdings2024-11-15 12:00 EST

Bio-Path Holdings Reports Third Quarter 2024 Financial Results

View all latest news

Benitec Biopharma

Genetic Medicine Company Benitec Biopharma develops genetic medicines for neuromuscular and other inherited disorders. Its approach combines gene silencing with gene replacement in a single therapeutic construct. Silence and Replace Platform The company's DNA-directed RNA interference technology is designed to suppress expression of a...

Recent company news

BNTCBenitec Biopharma2026-10-28 12:00 EST

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301

BNTCBenitec Biopharma2026-10-05 12:00 EST

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

BNTCBenitec Biopharma2026-09-14 20:00 EST

Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update

BNTCBenitec Biopharma2026-05-14 12:00 EST

Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update

BNTCBenitec Biopharma2026-04-28 11:00 EST

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

Stock data

Close
8.64 USD
Market cap
363.47M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States